14.52%QQQQ 35.13 12.16%XLF 16.28 7.81%
The Global Business News Leader | Tuesday, 14 Oct 2008
- EQUITY MARKETS
- BONDS AND RATES
- FOREX
- COMMODITIES
- LANGUAGES
- FUNDS
- RETIREMENT
- TAXES
- INSURANCE
- LANGUAGES
- MOVIE
- MUSIC
- TV
- CELEBRITIES
- LANGUAGES
ENZON PHARM INC
ENZN (NASDAQ)
$ 5.25 
Change: +0.73 +13.9% | Volume: 484,510
Change: +0.73 +13.9% | Volume: 484,510
Sponsored by 
ENZON PHARMA - Fundamental Profile
Company Information
| Ticker Symbol: | ENZN |
|---|---|
| Exchange: | NASD |
| Contact Info: | 685 Route 202/206 Bridgewater NJ 08807 908 541-8600 |
| CEO/President: | Jeffrey H. Buchalter |
| Industry: | Medical - Biomedical / Standard Industry Code: 2836 |
| Description: | Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets ABELCET, ONCASPAR, ADAGEN, and DEPOCYT in the United States. In addition, Enzon also receives royalties on sales of PEG-INTRON, marketed by Schering-Plough Corporation, and MACUGEN, marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized Linker Technology PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon also utilizes contract manufacturing opportunities to broaden its revenue base and enhance its organizational productivity. Enzon complements its internal research and development efforts with strategic initiatives. |
Share Information
| Shares Outstanding: | 44,730 (000) | Market Value: | 209,120 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 54.55% | Number of Inst.Shareholders: | 10.75% |
| Last Quarter Sales: | 50.96 ($Mil.) | Last Quarter Net Income: | -1.75 ($Mil.) |
| Last Quarter EPS: | -0.01 | P/E Ratio: | 466 |
| Most Recent Earnings: | -0.04 on 08/06/08 | Earnings Per Share: | 1.23 |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |
Data Provided By Barchart.com
CoreData does not represent, warrant, or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever to any party on account of any incompleteness of, inaccuracies in or untimeliness of the CoreData content provided hereunder, or for any delay in reporting such data. CoreData expressly disclaims all warranties of fitness of the CoreData content or computations and analyses thereof for a particular purpose or use.
Most Popular 
ENZN
Companies
IBT
- Analysts: GM would need cash to acquire Chrysler
- Bush to announce expanded bank bailout details
- Redstone's vehicle wraps CBS, Viacom stake sale
- British banks to get cash infusion from government
- Tesoro's shares jump on upbeat 3Q guidance
- Procter & Gamble to face uneasy shareholders
- HK legislators criticize regulators over bonds
- Silver – What’s Left?
- Vanessa Hudgens Make out Pictures with Bobby Bones
- USD/CAD - US Dollar Canadian Dollar, American Session - 13/10/08
- Columbus Day Parade Marches Through Manhattan
- Julian Robertson Sees Poor Economy for Next 10 to 15 Years
- Pizza Eating Record: Joey Chestnut eats 45 slices in 10 minutes
- Beyonces New Videos Premiere Monday for "If I Were a Boy" and "Single Ladies"
Top Competitors
| AMGEN |  |
-10.70 | 50.26 |
| GILEAD SCIENCES | |
-19.00 | 40.04 |
| GENENTECH INC |  |
+0.80 | 78.75 |
| CELGENE CP | |
-22.80 | 56.55 |
| BIOGEN IDEC INC | |
-30.50 | 44.76 |
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives